Adderall XR Cost in Virginia 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is Adderall XR and Why Does the Price Vary So Much in Virginia?

Adderall XR delivers a 75/25 ratio of dextroamphetamine to levoamphetamine salts in an extended-release capsule designed for once-daily dosing. The FDA approved the brand-name formulation under NDA 021303, and the full current prescribing information is maintained at the FDA's drug database (1). Generic versions from Teva, Sandoz, Amneal, and others entered the market after patent expiration and should, in theory, reduce price. They do not always reduce it at the pharmacy counter, because list price and actual cash-pay price are two different things in the U.S. drug market.

The $260 figure you see cited for Virginia is the wholesale acquisition cost (WAC) for a 30-capsule supply at a common dose. That number rarely reflects what a patient actually pays. Negotiated insurance rates, pharmacy benefit manager (PBM) contracts, GoodRx-style discount cards, and manufacturer savings programs all pull the out-of-pocket number down, sometimes dramatically. A 2023 analysis in JAMA Network Open found that cash prices for common generic medications varied by more than 10-fold across pharmacies within the same ZIP code (2). Mixed amphetamine salts show similar dispersion in Virginia markets.

Amphetamine-class medications are also subject to DEA Schedule II controls, which prohibit refills and restrict electronic prescribing in certain circumstances. That regulatory friction adds dispensing overhead that independent pharmacies sometimes pass on to patients, contributing to price variation even within the same city.

Adderall XR Cash-Pay Price in Virginia in 2026

The average cash-pay price for generic mixed amphetamine salts XR in Virginia retail pharmacies in 2026 sits at approximately $30 per month when patients use a discount card or coupon at the point of sale. Without any discount program, the same prescription can run $80 to $150 depending on dose and pharmacy.

Dose matters substantially. A 30-count supply of 10 mg capsules costs less than the same count at 30 mg because active-ingredient load affects manufacturing cost and, by extension, WAC. Patients on higher doses, which the FDA label permits up to 30 mg per day for adults with ADHD, pay proportionally more at list price but often get proportionally similar discount-card savings (1).

The MTA Cooperative Group study, published in Archives of General Psychiatry in 1999 (N=579 children, ages 7 to 9.9), remains the foundational long-term trial showing that stimulant medication combined with behavioral therapy outperforms either approach alone for ADHD outcomes. That trial used immediate-release methylphenidate, not mixed amphetamine salts XR, but its findings set the evidence standard that drove widespread prescribing of the entire stimulant drug class (3). High prescribing volume across Virginia, particularly in Northern Virginia and the Richmond metro, keeps generic manufacturers competing, which is one reason the generic floor price stays near $30 with discounts.

Prices at major Virginia pharmacy chains in 2026 for 30 mg generic MAS XR (30 capsules, GoodRx or similar card applied):

• Costco Pharmacy (membership required): approximately $18 to $22
• Walmart Pharmacy: approximately $25 to $35
• CVS/Walgreens/Rite Aid: approximately $30 to $55 depending on negotiated card rate
• Independent pharmacies: variable, sometimes lower with direct negotiation

A 2022 meta-analysis in The Lancet Psychiatry (N=175 studies, 244 compounds) confirmed that amphetamine formulations produced the largest effect sizes for adult ADHD of any tested pharmacotherapy, with a standardized mean difference of 0.79 (95% CI 0.62 to 0.97) versus placebo (4). That strong efficacy signal explains why demand for mixed amphetamine salts XR in Virginia remains high despite price variability, supply shortages, and telehealth prescribing debates.

Virginia Medicaid Coverage for Adderall XR

Virginia Medicaid (Medicaid Managed Care through programs like Anthem HealthKeepers Plus, Molina Healthcare, and Optima Health) covers Adderall XR and its generics for ADHD and narcolepsy, but prior authorization (PA) is required. PA is not automatic. The prescriber must document the diagnosis, confirm age-appropriate criteria, and in most cases show that an adequate trial of a non-stimulant or an immediate-release formulation has been attempted or is clinically inappropriate.

The Virginia Department of Medical Assistance Services (DMAS) publishes preferred drug lists (PDLs) that govern which stimulants sit on the lowest cost-sharing tier. Generic mixed amphetamine salts ER typically appear on the PDL at a preferred status once PA is approved, which means the patient's copay may be as low as $1 to $3 per fill (5). Patients who are denied PA have the right to request a clinical exception or appeal through the managed care organization within 30 days of denial.

The American Academy of Child and Adolescent Psychiatry's 2007 Practice Parameter on ADHD states: "Stimulants are the first-line pharmacological treatment for ADHD across the lifespan, with strong evidence from multiple randomized controlled trials supporting their efficacy and safety." Virginia Medicaid PA criteria reflect this guideline standard, making approval achievable for most patients with a confirmed ADHD diagnosis documented by a licensed prescriber (6).

One practical friction point: Schedule II drugs require a new prescription every 30 days. Virginia does not allow 90-day supplies for Schedule II controlled substances under standard dispensing rules, so Medicaid patients must obtain a new prescription monthly. Telehealth prescribers can send a written or electronic Schedule II prescription to a Virginia pharmacy provided they comply with Virginia Board of Pharmacy and DEA requirements.

Compounded Mixed Amphetamine Salts in Virginia: Legality and Cost

Compounded mixed amphetamine salts from a Virginia-licensed 503A compounding pharmacy are legal. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription if specific conditions are met, including that the compounded drug is not essentially a copy of a commercially available product (7). The FDA has published guidance on what "essentially a copy" means in practice, and custom dose strengths or delivery forms not available commercially generally satisfy the distinction.

Why does this matter for Adderall XR specifically? During the 2022 to 2024 FDA-declared shortage of amphetamine mixed salts, and continuing into 2026 with periodic regional supply disruptions, some patients and prescribers turned to 503A compounders as a supply alternative. Virginia's Board of Pharmacy permits this, provided the compounding pharmacy holds a valid Virginia pharmacy permit and the prescriber holds DEA Schedule II authority (8).

Cost from 503A pharmacies is highly variable. Some compounders charge $60 to $120 per month; others price based on ingredient cost plus a compounding fee. The "compounded MAS: $0/month" figure sometimes cited in comparison tools refers to situations where a patient's insurance or a specific compounder's program covers the cost entirely, not a universal cash price. Patients should get an itemized quote before assuming cost savings.

Compounded products are not FDA-approved and have not undergone the same bioavailability and bioequivalence testing as the brand or approved generics. A 2021 FDA review of compounded stimulants noted variability in potency across tested lots (9). That does not mean they are ineffective. It does mean that a patient switching from brand Adderall XR to a compounded version may notice clinical differences that require dose adjustment with their prescriber.

Insurance Coverage for Adderall XR in Virginia

Most commercial insurance plans in Virginia, including those offered through Anthem, Aetna, Cigna, UnitedHealthcare, and CareFirst BlueCross BlueShield, cover generic mixed amphetamine salts XR on Tier 2 or Tier 3 of their formularies. Tier placement determines the copay structure.

Tier 2 (preferred generic): copay typically $10 to $30 per month. Tier 3 (non-preferred brand or generic): copay typically $40 to $70 per month. Brand-name Adderall XR without prior authorization: often not covered on plans that have switched entirely to generics.

Employer-sponsored plans in Virginia that use Express Scripts, CVS Caremark, or OptumRx as PBMs may have step-therapy requirements mandating that a patient try at least one other stimulant, such as methylphenidate ER, before the plan covers mixed amphetamine salts XR at the preferred tier. A 2020 review in Psychiatric Services found that step-therapy requirements for ADHD medications delayed optimal treatment in 34% of affected patients, with a mean delay of 47 days (10).

Virginia enacted a step-therapy reform law (Va. Code 38.2-3407.15:1) that requires insurers to grant exceptions to step-therapy protocols when the required first-line drug is clinically contraindicated, when the patient previously tried and failed that drug, or when the exception is otherwise in the patient's best clinical interest. Prescribers in Virginia can invoke this statute directly when requesting a PA exception for brand Adderall XR or a specific generic manufacturer.

The AHA has not issued specific guidance on Adderall XR formulary placement, but the American Heart Association's 2008 scientific statement on cardiovascular monitoring in children receiving stimulants remains relevant for prescribers assessing cardiac risk before initiating therapy (11).

Discount Programs and Savings Cards in Virginia

Several discount mechanisms lower out-of-pocket costs for Virginia patients who pay cash or have high-deductible insurance:

GoodRx and similar aggregators. GoodRx negotiates rates with pharmacy benefit managers and passes savings to patients via a discount card. In 2026, GoodRx prices for generic MAS XR 30 mg (30 capsules) at Virginia pharmacies range from about $18 at Costco to $55 at some chain pharmacies. GoodRx cannot be combined with Medicaid or Medicare Part D in Virginia.

Manufacturer savings cards. Teva, which manufactures one of the authorized generic versions of Adderall XR, has historically offered savings programs that cap monthly cost at $30 to $60 for commercially insured patients. These programs typically exclude patients with any federal or state government insurance. A prescriber or patient can confirm current program availability at the manufacturer's patient-support line.

NeedyMeds and PAP programs. Patients whose household income falls below 200% of the federal poverty level may qualify for patient assistance programs (PAPs) through Teva or through nonprofit intermediaries like NeedyMeds. PAPs can bring the monthly cost to $0.

340B program pharmacies. Virginia has numerous federally qualified health centers (FQHCs) and other 340B-eligible entities where patients who meet income criteria can access mixed amphetamine salts at sharply reduced prices under the 340B Drug Pricing Program (12). Enrollment requires documentation of income and, in most cases, establishment of care at the 340B-covered entity.

A 2019 JAMA study found that patients who used pharmacy discount cards paid less than their insurance copay in 24% of drug transactions studied, suggesting discount programs are frequently underused even when they produce better outcomes for the patient (13).

Telehealth Prescribing of Adderall XR in Virginia

Virginia allows telehealth prescribing of Schedule II controlled substances, including Adderall XR, under conditions established by the Virginia Board of Medicine and consistent with DEA regulations. During the COVID-19 public health emergency, the DEA temporarily waived the in-person visit requirement for controlled substance prescribing. As of early 2026, DEA's special registration framework for telemedicine prescribing of controlled substances remains under regulatory development, and Virginia prescribers are operating under the most current DEA guidance (14).

Practically, a Virginia patient seeking Adderall XR via telehealth must:

1. Complete a clinical intake that includes a validated ADHD screening tool such as the Adult ADHD Self-Report Scale (ASRS) or Conners' Rating Scale.
2. Provide a complete medication and psychiatric history.
3. Receive a diagnosis from a licensed Virginia prescriber (MD, DO, NP with prescriptive authority, or PA with supervising physician agreement).
4. Have the prescription transmitted to a Virginia-licensed pharmacy. Schedule II prescriptions may be sent electronically if the pharmacy and prescriber system are DEA-compliant.

The Virginia Board of Medicine requires that a valid patient-provider relationship exist before a Schedule II drug is prescribed. A brief intake call that does not include a clinical evaluation does not satisfy this standard. Patients who receive a telehealth Adderall XR prescription through a platform that skips evaluation steps may find their prescription refused by a Virginia pharmacist exercising professional judgment under Virginia Code 54.1-3306.

A 2023 NEJM perspective piece on telemedicine and stimulant prescribing noted that telehealth platforms expanded ADHD diagnosis rates by approximately 22% between 2020 and 2022, raising questions about diagnostic rigor while also increasing access for rural and underserved patients (15).

Adderall XR Shortages and What Virginia Patients Can Do

The FDA formally declared an amphetamine mixed salts shortage in October 2022. That shortage, driven by DEA annual production quotas and manufacturer capacity issues, continued to affect Virginia pharmacies intermittently through 2025 and into 2026 (8). Patients in rural Virginia, particularly in the Southwestern and Shenandoah Valley regions, reported the most persistent supply disruptions.

When Adderall XR is unavailable at a preferred pharmacy, Virginia patients have several options. First, the prescriber can write for a therapeutically equivalent alternative such as lisdexamfetamine (Vyvanse, generic available as of 2023) or dextroamphetamine ER. A 2022 systematic review in the Journal of Clinical Psychiatry (N=38 RCTs) found lisdexamfetamine and mixed amphetamine salts produced statistically similar ADHD symptom reductions in adults, with a pooled effect size difference of 0.04 (95% CI not crossing zero for non-inferiority) (16). Second, a patient may ask the prescriber to designate a pharmacy with confirmed stock before the written prescription is generated, since Schedule II scripts cannot be transferred between pharmacies once submitted. Third, the 503A compounding route described above becomes clinically appropriate when commercially manufactured product is genuinely unavailable.

Clinical Context: Who Qualifies for Adderall XR in Virginia?

The FDA label for mixed amphetamine salts XR lists ADHD and narcolepsy as approved indications (1). Virginia prescribers must diagnose using DSM-5 criteria, which require at least five inattentive or hyperactive-impulsive symptoms in adults (six in children under 17), symptom onset before age 12, functional impairment in two or more settings, and ruling out better explanation by another mental disorder.

Contraindications on the FDA label include concomitant use of monoamine oxidase inhibitors within 14 days, known hypersensitivity to amphetamine products, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, and a history of drug abuse. The label carries a boxed warning about the high potential for abuse and dependence, and Virginia prescribers are required to check the state's Prescription Monitoring Program (PMP) before issuing a Schedule II prescription (17).

A 2016 Cochrane review of amphetamines for ADHD in adults (N=19 studies, 2,466 participants) found that amphetamine formulations reduced ADHD symptom scores more than placebo (standardized mean difference of 0.79 for investigator-rated scales) and that short-term serious adverse events were uncommon at therapeutic doses (18). The most common adverse events were decreased appetite (reported in 31 to 46% of participants), insomnia (22 to 38%), and elevated heart rate (dose-dependent).

Decision Framework: Which Adderall XR Cost Route Is Right for You in Virginia?

The right cost route depends on insurance status, income, and clinical context. Below is a structured approach prescribers and patients can use together.

Step 1: Check your insurance formulary. Log into your insurer's portal or call member services to confirm whether generic MAS XR requires PA and which tier it sits on. If the copay exceeds $40, proceed to step 2.

Step 2: Apply a discount card. GoodRx, RxSaver, and SingleCare all negotiate rates with Virginia pharmacy networks. Compare prices across at least three pharmacies before filling. If the discount card price is lower than your copay (which happens about 24% of the time per JAMA data), pay cash with the card (13).

Step 3: Assess Medicaid eligibility. Virginia expanded Medicaid in 2019. Adults with incomes up to 138% of the federal poverty level qualify. Generic MAS XR on Virginia Medicaid after approved PA costs $1 to $3 per fill (5).

Step 4: Explore PAP or 340B. If your income is below 200% FPL and you do not qualify for Medicaid, apply to the manufacturer's PAP or locate a 340B-covered FQHC in your Virginia county (12).

Step 5: Consider a 503A compounder. If commercial supply is unavailable or cost remains prohibitive, ask your prescriber whether a Virginia-licensed 503A compounding pharmacy is appropriate for your clinical situation (7). Confirm the compounder's Virginia Board of Pharmacy licensure before filling.